Editas Medicine (EDIT) said late Thursday that it will focus on in vivo CRISPR-edited medicines and end the development of reni-cel to optimize cost structure and extend cash runway into Q2 2027.
The strategic transition will help the company accelerate in vivo human proof of concept in about two years, the company said.
Editas said it will also eliminate 65% of its workforce over the next six months. Chief Medical Officer Baisong Mei will leave the company, while Jessica Hopfield will become chair of the board on Dec. 31.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。